<DOC>
	<DOCNO>NCT00688467</DOCNO>
	<brief_summary>Evaluation treatment participant mild asthma .</brief_summary>
	<brief_title>Efficacy Safety Navarixin ( SCH 527123 ) Participants With Allergen-Induced Asthma ( P05363 )</brief_title>
	<detailed_description>To evaluate effect navarixin ( MK-527123 , SCH 527123 ) treatment allergen-induced late asthmatic response ( LAR ) participant mild asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Man woman 18 65 year age race . Has mild , stable , allergic asthma define American Thoracic Society criterion . Has history episodic wheeze shortness breath . Has Forced Expiratory Volume 1 second ( FEV1 ) least 70 % predict Screening within 10 % preallergen screen value baseline . Has positive methacholine challenge Screening . Methacholine challenge consider positive decrease least 20 % FEV1 occur concentration less equal 16 mg/mL . Baseline methacholine PC20 ( concentration initiate 20 % fall FEV1 ) must within 1 double concentration preallergen screen PC20 enter treatment . Has positive skinprick test common allergen ( cat , dust mite , grass , pollen ) . Has positive Early Asthmatic Response &gt; =20 % fall FEV1 measure FEV1 immediately prior challenge , Late Asthmatic Response &gt; =15 % fall FEV1 FEV1 measure immediately prior challenge Screening period . Has free asthma exacerbation least 4 week Screening . An exacerbation define occurrence clinical deterioration asthma require emergency treatment , hospitalization due asthma , treatment additional medication , judge clinical investigator . Has free relevant seasonal allergen exposure least 4 week study able remain duration study . Has current nonsmoking status . If previous smoker , cumulative smoking history must fewer 10 packyears ( packyear=20 cigarette smoke daily 1 year ) . Previous smoker must smoke within 1 year Screening . Is willing give write informed consent participate study . Has ability comply dose regimen , adhere visit schedule , participate treatment procedure , include sputum induction . Female participant childbearing potential must negative serum pregnancy test ( human chorionic gonadotropin ; hCG ) Screening must use medically acceptable , highly effective , adequate form birth control ( ie , failure rate &lt; 1 % per year use consistently correctly ) prior Screening agrees continue use study ( Screening Treatment Periods ) . Medically acceptable , highly effective form birth control include hormonal implant , oral contraceptive , hormonal patch , intravaginal ring , medically acceptable prescribed intrauterine device ( IUDs ) , monogamous relationship male partner vasectomy . A female participant childbearing potential must medical record surgically sterile ( eg , hysterectomy , tubal ligation ) , least 1 year postmenopausal . Absence menses least 1 year indicate female postmenopausal . A female participant encourage continue use highly effective method birth control 30 day follow end treatment . Participants , male sexually active woman childbearing potential , must agree use adequate form contraception duration study sexual relation woman use highly effective birth control method . Clinical laboratory test ( complete blood count [ CBC ] , blood chemistry , urinalysis ) must within normal limit clinically acceptable investigator/sponsor . Has diagnosis chronic obstructive pulmonary disease ( COPD ) clinically relevant lung disease ( eg , cystic fibrosis , pulmonary fibrosis , bronchiectasis ) mild allergic asthma , history intubate . Has worsen respiratory tract infection within 4 week Screening . Has clinically significant abnormality ; history clinically significant hypotensive episode fainting , dizziness , lightheadedness ; history symptom cardiovascular disease ; significant neurologic disease ; hematologic abnormality , include coagulopathy ; medication regimen clinically relevant medical condition asthma may interfere effect study medication . Had peripheral blood neutrophil ( PBN ) count &lt; 3 Ã— 10^9/L Screening Visit . Has allergy/sensitivity study drug excipients . Is pregnant , breastfeeding , intend become pregnant study . Has use investigational drug within 30 day 5 halflives Screening . Is presently participate clinical study . Is part staff personnel directly involve study Is family member investigational study staff . Has receive treatment prohibit protocol ( Table 3 ) , medication may interfere effect study medication recently indicate washout period prior Screening , must continue receive prohibit treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neutrophilic Asthma</keyword>
</DOC>